Cynosure Appoints H. Travis Lee as Vice President of Global Marketing
May 14 2008 - 8:30AM
PR Newswire (US)
WESTFORD, Mass., May 14 /PRNewswire-FirstCall/ -- Cynosure, Inc.
(NASDAQ:CYNO), a leading developer and manufacturer of a broad
array of light-based aesthetic treatment systems, today announced
the appointment of H. Travis Lee as vice president of global
marketing. Lee will develop and implement worldwide strategic
marketing initiatives for all of Cynosure's flagship products,
including the Smartlipo MPX, the company's newest system for laser
lipolysis, which will debut internationally in the second half of
this year. "As a global marketing executive, Travis has produced
outstanding results in a career that spans more than two decades
and includes two of the medical device industry's leading companies
-- Smith & Nephew and Boston Scientific," said Cynosure
President and Chief Executive Officer Michael Davin. "Colleagues
and co-workers praise his ability to articulate brand value,
cultivate strong relationships with key opinion leaders and
identify new business opportunities." Lee joined Cynosure from the
global medical technology company Smith & Nephew Inc., where he
served as global director of marketing for the endoscopy division,
with responsibility for two franchises that accounted for more than
$300 million in revenue. In addition to building and leading the
department, he developed key opinion leaders and integrated them
into the division's product development process, and led the
efforts behind two significant acquisition targets. Prior to that
he worked for more than five years at Boston Scientific Corp., a
manufacturer of products for minimally invasive surgical
procedures, first as principal product manager in the
urology/gynecology division and then as group product manager in
the neurovascular division. In this role he had global
responsibility for a product line with 70% worldwide market share.
In addition, Lee has worked in executive marketing positions for
companies including Cell Robotics, Inc., Medasonics, Inc., Xintec
Corp. and Heraeus Surgical Inc., which was later acquired by
Laserscope. Among his accomplishments at Heraeus Surgical, Lee
managed the investigation, implementation and launch of a new CO2
laser system for cosmetic applications that generated more than $10
million in sales in less than six months. He also successfully
launched four new capital laser equipment products and more than 10
new disposable and reusable laser accessories in his first year.
"Cynosure has built an international reputation for technology
innovation and product excellence," Lee said. "With the
international launch of the Smartlipo MPX scheduled for the second
half of this year, this is a particularly exciting time to join the
company. I look forward to leading the marketing team as we focus
on continuing the success that has established Cynosure as the
fastest-growing company in the aesthetic industry." About Cynosure,
Inc. Cynosure, Inc. develops and markets aesthetic treatment
systems that are used by physicians and other practitioners to
perform non-invasive and minimally invasive procedures to remove
hair, treat vascular lesions, rejuvenate skin through the treatment
of shallow vascular and pigmented lesions, laser lipolysis and
temporarily reduce the appearance of cellulite. Cynosure's products
include a broad range of laser and other light-based energy
sources, including Alexandrite, pulsed dye, Nd:YAG and diode
lasers, as well as intense pulsed light. Cynosure was founded in
1991. For corporate or product information, contact Cynosure at
800-886-2966, or visit http://www.cynosure.com/. Safe Harbor Any
statements in this press release about future expectations, plans
and prospects for Cynosure, Inc., including statements about the
company's expectations and future financial performance, as well as
other statements containing the words "believes," "anticipates,"
"plans," "expects," "will" and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including Cynosure's
reliance on sole source suppliers, the inability to accurately
predict the timing or outcome of regulatory decisions, changes in
consumer preferences, competition in the aesthetic laser industry,
economic, market, technological and other factors discussed in
Cynosure's most recent Annual Report on Form 10-K, which is filed
with the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
Cynosure's views as of the date of this press release. Cynosure
anticipates that subsequent events and developments will cause its
views to change. However, while Cynosure may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Cynosure's views as of any date subsequent to the date
of this press release. DATASOURCE: Cynosure, Inc. CONTACT: Scott
Solomon, Vice President of Sharon Merrill Associates, Inc. for
Cynosure, Inc., +1-617-542-5300, Web site: http://www.cynosure.com/
Copyright
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From May 2024 to Jun 2024
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From Jun 2023 to Jun 2024